InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
无可用的信号评分。
Browse the detailed record of transactions filed by Kowalsky Matthew Paul. Director active across 2 companies, notably Sigilon Therapeutics, Inc.. In total, 2 reports have been published. Activity tracked since 12 February 2026. The latest transaction was disclosed on 12 February 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 条申报中的 2 条